Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.

[1]  P. Karakiewicz,et al.  Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria. , 2011, European urology.

[2]  N. Rioux-Leclercq,et al.  Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. , 2010, Urology.

[3]  P. Tan,et al.  Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. , 2010, Urology.

[4]  R. Figlin,et al.  The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). , 2010 .

[5]  C. Porta,et al.  Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. , 2010, Kidney international.

[6]  U. Capitanio,et al.  Erratum: Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection (BJU International (2009) 103 (1368-1374)) , 2010 .

[7]  T. Skolarus,et al.  Percent microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma. , 2010, The Journal of urology.

[8]  C. Porta,et al.  Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. , 2010, Cancer treatment reviews.

[9]  K. Ogan,et al.  Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. , 2010, The Journal of urology.

[10]  Ming Zhou,et al.  Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. , 2010, Urology.

[11]  R. Uzzo,et al.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Patard,et al.  Conditional survival predictions after nephrectomy for renal cell carcinoma. , 2009, The Journal of urology.

[14]  J. Brooks,et al.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma , 2009, BMC clinical pathology.

[15]  F. Montorsi,et al.  Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study , 2009, Clinical Cancer Research.

[16]  J. Patard,et al.  Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. , 2009, The Journal of urology.

[17]  N. Marcussen,et al.  Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Figlin,et al.  Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α , 2009, Cancer.

[19]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Figlin,et al.  Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Lohse,et al.  Development and evaluation of BioScore , 2009, Cancer.

[22]  U. Capitanio,et al.  Impact of clinical factors, including a point‐of‐care nuclear matrix protein‐22 assay and cytology, on bladder cancer detection , 2009, BJU international.

[23]  A. Belldegrun,et al.  Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. , 2009, The Journal of urology.

[24]  Q. Fu,et al.  Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: A 15‐year single center experience , 2009, International journal of urology : official journal of the Japanese Urological Association.

[25]  A. Belldegrun,et al.  Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy , 2009, Cancer Epidemiology Biomarkers & Prevention.

[26]  K. Bensalah,et al.  A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. , 2009, European urology.

[27]  Y. Chu,et al.  The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase‐2 expression in clear cell renal cell carcinoma , 2009, BJU international.

[28]  U. Capitanio,et al.  Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.

[29]  M. Brunelli,et al.  The ‘Stage, Size, Grade and Necrosis’ score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer‐specific survival in patients with clear cell renal cell carcinoma , 2009, BJU international.

[30]  飯村 康正.  Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification : the TNM-C score , 2009 .

[31]  M. Kattan,et al.  Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma , 2008, Cancer.

[32]  S. Loening,et al.  Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. , 2008, Cancer letters.

[33]  K. Rock,et al.  Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas , 2008, Clinical Cancer Research.

[34]  F. Waldman,et al.  von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. , 2008, The Journal of urology.

[35]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[36]  J. Tostain,et al.  Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. , 2008, The Journal of urology.

[37]  M. Michaelson,et al.  Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  N. Rioux-Leclercq,et al.  Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma , 2008, International journal of cancer.

[39]  Paolo Chiodini,et al.  Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy , 2008, Cancer.

[40]  M. Kattan,et al.  Preoperative nomogram predicting 12-year probability of metastatic renal cancer. , 2008, The Journal of urology.

[41]  R. Figlin,et al.  Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor , 2008 .

[42]  R. Motzer,et al.  Hypoxia-inducible factor (HIF) 1{alpha} and 2{alpha} levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) , 2008 .

[43]  H. Lane,et al.  Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Lohse,et al.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma , 2008, Cancer.

[45]  Y. Lotan,et al.  Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma , 2008, BJU international.

[46]  Stefano Cavalleri,et al.  Mathematical Models for Prognostic Prediction in Patients with Renal Cell Carcinoma , 2008, Urologia Internationalis.

[47]  B. Jasani,et al.  Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma , 2008, British Journal of Cancer.

[48]  S. Staibano,et al.  Survivin Expression in Renal Cell Carcinoma , 2008, Cancer investigation.

[49]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[50]  J. Patard,et al.  Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram , 2007, BJU international.

[51]  M. Zhou,et al.  Renal mass biopsy--a renaissance? , 2008, The Journal of urology.

[52]  T. Deguchi,et al.  Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. , 2008, Oncology reports.

[53]  David B Seligson,et al.  Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[54]  S. Signoretti,et al.  Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. , 2007, Clinical genitourinary cancer.

[55]  J. Patard,et al.  Patients with renal cell carcinoma nodal metastases can be accurately identified: External validation of a new nomogram , 2007, International journal of cancer.

[56]  A. Ravaud,et al.  Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. , 2007, The Journal of urology.

[57]  J. Patard,et al.  Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. , 2007, European urology.

[58]  J. Cheville,et al.  Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  N. Rioux-Leclercq,et al.  Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. , 2007, Human pathology.

[60]  J. Cheville,et al.  Ki‐67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other , 2007, Cancer.

[61]  T. Choueiri,et al.  Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy , 2007, Cancer.

[62]  D. Bostwick,et al.  Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. , 2007, Archives of pathology & laboratory medicine.

[63]  John Smeraglia,et al.  Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins , 2007, Journal of Translational Medicine.

[64]  T. Klatte,et al.  Evaluation of peri‐operative peripheral and renal venous levels of pro‐ and anti‐angiogenic factors and their relevance in patients with renal cell carcinoma , 2007, BJU international.

[65]  F. Waldman,et al.  Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC) , 2007 .

[66]  K. Bensalah,et al.  Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. , 2007, European urology.

[67]  David B Seligson,et al.  Prognostic relevance of the mTOR pathway in renal cell carcinoma , 2007, Cancer.

[68]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[69]  Yair Lotan,et al.  Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence , 2007, The Prostate.

[70]  J. Patard,et al.  Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  Taiji Tsukamoto,et al.  Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. , 2007, The Journal of urology.

[72]  J. Cheville,et al.  Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[73]  J. Cheville,et al.  Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[74]  J. Cheville,et al.  Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. , 2007, The Journal of urology.

[75]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[76]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[77]  P. Rehak,et al.  Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. , 2007, European urology.

[78]  K. Grankvist,et al.  Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray , 2006 .

[79]  T. Chao,et al.  Increasing expression of fascin in renal cell carcinoma associated with clinicopathological parameters of aggressiveness. , 2006, Histology and histopathology.

[80]  K. Chew,et al.  Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status , 2006, BJU international.

[81]  N. Kawata,et al.  Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma. , 2006, Urology.

[82]  P. Rehak,et al.  Biologic significance of fascin expression in clear cell renal cell carcinoma: systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique. , 2006, Urology.

[83]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[84]  J. Cheville,et al.  High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma , 2006, Cancer.

[85]  K. Rock,et al.  Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. , 2006, The Lancet. Oncology.

[86]  H. von der Maase,et al.  Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  M. Mansukhani,et al.  Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. , 2006, Urology.

[88]  A. Toker,et al.  Akt signaling and cancer: surviving but not moving on. , 2006, Cancer research.

[89]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[90]  K. Haustermans,et al.  Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric Adenocarcinomas , 2006, Annals of surgery.

[91]  K. Bensalah,et al.  Prognostic value of thrombocytosis in renal cell carcinoma. , 2006, The Journal of urology.

[92]  J. Müller,et al.  Identifizierung von Biomarkern und therapeutischen Targets beim Nierenzellkarzinom mittels ProteinChip-Technologie , 2006, Der Urologe.

[93]  N. Marcussen,et al.  Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial , 2006, British Journal of Cancer.

[94]  J. Pastorek,et al.  Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis , 2006, Cancer investigation.

[95]  R. Motzer,et al.  Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma , 2005, Cancer.

[96]  K. Junker,et al.  [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology]. , 2006, Der Urologe. Ausg. A.

[97]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[98]  J. Cheville,et al.  Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma , 2005, Cancer.

[99]  J. Cheville,et al.  A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. , 2005, The Journal of urology.

[100]  D. Ovcharenko,et al.  Neutrophil gelatinase-associated lipocalin as a survival factor. , 2005, The Biochemical journal.

[101]  F. Guillé,et al.  Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy , 2005, Cancer.

[102]  J. Lam,et al.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. , 2005, The Journal of urology.

[103]  S. Horvath,et al.  Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma , 2005, Cancer.

[104]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[105]  Yair Lotan,et al.  Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. , 2005, The Journal of urology.

[106]  S. Horvath,et al.  Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.

[107]  K. Stoeber,et al.  Mcm2, Geminin, and KI67 Define Proliferative State and are Prognostic Markers in Renal Cell Carcinoma , 2005, Clinical Cancer Research.

[108]  Ian R. Drexler,et al.  Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. , 2005, The Journal of clinical investigation.

[109]  G. Gokce,et al.  Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma , 2005, Scandinavian journal of urology and nephrology.

[110]  K. Grankvist,et al.  The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  M. Kattan,et al.  A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. , 2005, The Journal of urology.

[113]  A. Concha,et al.  Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas , 2005, Cancer Immunology, Immunotherapy.

[114]  A. Ravaud,et al.  Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie , 2005, World Journal of Urology.

[115]  T. Olsson,et al.  Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma , 2004, Acta oncologica.

[116]  F. Guillé,et al.  Multi-institutional validation of a symptom based classification for renal cell carcinoma. , 2004, The Journal of urology.

[117]  N. Sonenberg,et al.  Upstream and downstream of mTOR. , 2004, Genes & development.

[118]  S. Horvath,et al.  Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma , 2004, Clinical Cancer Research.

[119]  J. Wunder,et al.  Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma , 2004, Clinical Cancer Research.

[120]  J. Blay,et al.  Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  S. Horvath,et al.  Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. , 2004, The Journal of urology.

[122]  T. Wheeler,et al.  Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  G. Gokce,et al.  Prognostic value of the expression of Ki‐67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma , 2004, BJU international.

[124]  P. Rehak,et al.  Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. , 2004, Urology.

[125]  S. Shariat,et al.  p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  C. Roehrborn,et al.  Survivin expression is associated with features of biologically aggressive prostate carcinoma , 2004, Cancer.

[127]  Sun-Ja Kim,et al.  Increased expression of caveolin‐1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma , 2004, BJU international.

[128]  G. Landberg,et al.  Expression of vascular endothelial growth factor protein in human renal cell carcinoma , 2004, BJU international.

[129]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[131]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[132]  R. Figlin,et al.  Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma , 2003, Cancer.

[133]  J. Cheville,et al.  A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. , 2003, The Journal of urology.

[134]  J. Patard,et al.  A preoperative clinical prognostic model for non‐metastatic renal cell carcinoma , 2003, BJU international.

[135]  D. Altieri.  Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.

[136]  D. McMillan,et al.  The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer , 2003, British Journal of Cancer.

[137]  M. Weller,et al.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. , 2003, Cancer research.

[138]  J. Závada,et al.  Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients , 2003, British Journal of Cancer.

[139]  E. Messing,et al.  Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.

[140]  S. Horvath,et al.  Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. , 2003, Urology.

[141]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[142]  M. Oya,et al.  Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. , 2003, The Journal of urology.

[143]  Donna Richardson,et al.  Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[145]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[146]  R. Figlin,et al.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  T. Oshikiri,et al.  Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma , 2002, British Journal of Cancer.

[148]  Pan‐Chyr Yang,et al.  Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. , 2002, The American journal of pathology.

[149]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[150]  B. Koçak,et al.  Value of urinary NMP-22 in patients with renal cell carcinoma. , 2002, Urology.

[151]  F. Marshall,et al.  Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. , 2002, The Journal of urology.

[152]  A. Ravaud,et al.  Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[153]  C. Suschek,et al.  Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas , 2002, International journal of cancer.

[154]  H. Levin,et al.  The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma. , 2002, Annals of diagnostic pathology.

[155]  H. Lehr,et al.  Loss of tumor suppressor protein PTEN during renal carcinogenesis , 2002, International journal of cancer.

[156]  S. Okushiba,et al.  Overexpression of caveolin‐1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage , 2002, Cancer.

[157]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[158]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[160]  M. Robinson,et al.  Caveolin-1 expression is associated with high-grade bladder cancer. , 2001, Urology.

[161]  C. Sheehan,et al.  Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[162]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[163]  L. Kavoussi,et al.  Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. , 2001, Urology.

[164]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[165]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[166]  H. Gröne,et al.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.

[167]  C. Ren,et al.  Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. , 2001, Cancer research.

[168]  F. Marshall,et al.  Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. , 2001, The American journal of pathology.

[169]  R. Persad,et al.  Reply , 2001, BJU international.

[170]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  H. Tarhan,et al.  p53 Mutations and Other Prognostic Factors of Renal Cell Carcinoma , 2001, Urologia Internationalis.

[172]  S. Curran,et al.  Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. , 2000, European journal of cancer.

[173]  V. Paradis,et al.  Expression of vascular endothelial growth factor in renal cell carcinomas , 2000, Virchows Archiv.

[174]  A. Renshaw,et al.  Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. , 2000, The American journal of surgical pathology.

[175]  S. Huang,et al.  Urinary NMP22 and renal cell carcinoma. , 2000, Urology.

[176]  K. Grankvist,et al.  Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. , 2000, The Journal of urology.

[177]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[178]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  M. Rubin,et al.  The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase–polymerase chain reaction assay for MN/CA9 , 1999, Cancer.

[180]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[181]  H. Radzun,et al.  Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. , 1998, The Journal of urology.

[182]  R. G. Anderson.  The caveolae membrane system. , 1998, Annual review of biochemistry.

[183]  L. Baert,et al.  Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. , 1998, Clinical and experimental immunology.

[184]  D. Kowalczyk,et al.  Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. , 1997, British journal of urology.

[185]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[186]  G. Martiny-Baron,et al.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.

[187]  H. Müller-Hermelink,et al.  Significance of conventional and new prognostic factors for locally confined renal cell carcinoma , 1995, Cancer.

[188]  H. Sengeløv,et al.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.

[189]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[190]  S. Johansson,et al.  The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[191]  J. Shimazaki,et al.  Changes on distribution of CD4+/CD45RA- and CD8+/CD11- cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression. , 1992, European urology.

[192]  R. Bahnson,et al.  Immunophenotypic markers in renal cell carcinoma. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[193]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[194]  D. Trump,et al.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.